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Abstract
Background: The aim of the present study is to assess the response rate and toxicity profile in patients with locally advanced rectal cancer using high 
dose rate endorectal brachytherapy (HDR-EBT) as a start component of the neoadjuvant treatment.
Material and methods: 28 patients with T3-4N0-2M0 rectal adenocarcinoma were included in the study. A novel approach using HDR-EBT is given in 4 
fractions (4 Gy per fraction, 2 times a week) in combination with external beam radiotherapy (EBRT) 30,6 Gy (1,8 Gy per fraction). All patients received 
neoadjuvant chemotherapy during the course of irradiation consisting of Capecitabine 825 mg/m2 per os daily.
results: The majority of patients were males (n=16; 57.1%), 12 (42.9%) – were females, their mean age was 60,6 years. All patients had a decrease in 
tumor size from average of 4,88 cm to 3,14 cm longitudinally. 21 of 28 patients (75%) had sphincter preserving surgery. 17 of 28 patients (60.7%) had a 
pathologic complete response of their primary tumors. Radiation therapy was well-tolerated. Acute GI and GU toxicity was limited to ≤ Grade 2 for all 
patients. Local recurrence in the observation group within 2 years was 3.6%.
conclusions: The use of HDR-EBT as a start component of the neoadjuvant locally advanced rectal cancer treatment is an acceptable modality with high 
pathological response rate as well as an acceptable toxicity profile.
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Introduction
Neoadjuvant chemoradiotherapy with further rectal 
cancer surgery at the present day is a standard in the locally 
advanced rectal cancer (RC) treatment [1]. It is known that 
use of high dose rate endorectal brachytherapy (HDR-EBT) 
at the preoperative stage in the treatment of RC especially the 
low-localization tumors, leads to an improvement of a local 
control and possibility of the sphincter-saving procedure [2]. 
In spite of the resounding success of use of an intracavitary 
irradiation in complex curative or individual palliative therapy 
of RC, the problem of use of a contact gamma-therapy at this 
nosology is remote from a final solution. In particular, bri-
ght-line rules at the level of a cumulative doze (CD) from the 
present component of the radiotherapy, fractionating regimes 
and, in particular, an order of combination of HDR-EBT with 
other methods of the antineoplastic impact are absent. 
The aim of the present study is to assess the response rate 
and toxicity profile in patients with locally advanced RC using 
HDR-EBT as a start component of the neoadjuvant treatment.
Material and methods
 28 patients with the locally advanced primary unresectable 
RC of stage T3-4N0-2M0 were examined and they underwent 
a treatment due to the submitted regimen in 2011-2013 in 
Kherson Regional Oncological Dispensary.
Patients underwent HDR-EBT given in 4 fractions (4 Gy 
per fraction, 2 times a week) in combination with external 
beam radiotherapy (EBRT) 30,6 Gy (1,8 Gy per fraction). All 
patients on the first day of the radiotherapy received HDR-
EBT session, in further HDR-EBT was conducted 2 times per 
week (Monday, Thursday), and EBRT was placed on days free 
of HDR-EBT.
EBRT was conducted with the use of device “Teragam 
К-01” (source activity 60Со 177 ТBq, 1,17-1,33 MeV) per 
pelvis region. Lower limit of fields was situated 2 cm lower 
of an anal edge, upper limit - at the level L5-S1, lateral – 1 
cm laterally of a bone pelvic ring. For the performance of 
3D-planning on the system «PlanW 2000», axial plane CT 
series were used, that eventually led to the formation of the 
opposite fields 16–16 × 18–18 cm depending on the consti-
tutional particulars of a patient. 
HDR-EBT was conducted with the use of device 
«MultiSourсe» (source activity 60Со 70 ТBq). Before the 
conduction of HDR-EBT a tumor size, a depth of the rectal 
wall invasion, a tumor prevalence were considered with the 
relation to the anal canal. Type and sizes of an applicator 
were chosen depending on a radiation area and anatomy of 
a patient. Planning was performed on the basis of MRI in a 
planning system «HDRplus 2.6».
Diagnosis of the underlying disease of all patients was 
morphologically verified. All tumors were an adenocarcinoma 
G2. All patients underwent radiotherapy with a Capecitabine 
radiosensitization with a daily doze of 825 mg/m2 per os.
There were men 57.1% (n=16) and women – 42.9% (n=12) 
under investigation. Age of patients varied within the range 
of 39-77 years (on average 60.6). Tumors of the rectal lower 
ampulla were present in 12 (42.9%) and the rectal middle 
ampule – in 16 (57.1%) cases. Pain was present in 20 (71.4%) 
of patients before treatment given. Chronic rectal bleeding 
was present in 13 (46,4%) of patients. 9 (32,1%) of patients 
suffered from a constipation at the beginning of the treatment. 
Distance between an anus and a distal pole of a tumor before 
therapy amounted to 2-9 cm (on average 5,55 cm). Extension 
of a primary tumor along the length of a rectum amounted 
from 2 to 10 cm (on average 4,88 cm). 
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Results and discussion
Total pain relief after the treatment given was reached in 12 
(42.9%), partial pain relief – in 8 (28.6%) of patients. Chronic 
rectal bleeding was negated in 92.9% of cases. Constipation 
disappeared for the moment of the treatment termination in 
all cases. Distance between an anus and a distal pole of a tumor 
after therapy increased on average to 1,35 cm, extension of a 
primary tumor diminished to 3,14 cm (on 35.6%). 
Some studies showed that combined radiotherapy is more 
effective in rectal tumor downstaging than EBRT alone and 
achieves a significant improvement in sphincter-saving pro-
cedure up to 76% in T2-T3 RC [3]. RC downstaging into a 
resectable stage was evaluated during a control examination in 
4-6 weeks after completion of a radiotherapy (MRI, edoscopy) 
in our study, and amounted to 96.4% of cases (27 patients). 6 
(21.4%) of patients were not candidates for sphincter-saving 
procedures. The number of the sphincter-saving procedures 
amounted to 21 (75%). Surgery was not performed in 1 (3.6%) 
patient. Reason of rejection of a surgery treatment was unre-
sectable tumor. In the post-surgery period 1 case of sigmoido-
proctostomy deficiency and 1 postoperative urinary bladder 
atony were noticed that amounted to 3.6% (total number of 
the postoperative complications didn’t exceed 7.2%, which 
is comparable with statistical number of the postoperative 
complications in Ukraine and in the world).
It is known that HDR-EBT has advantages in the tumor 
destruction, but it also has disadvantages which are associated 
with the risk of complications [4]. During the whole course 
of a radiotherapy any undesirable effects were absent for 6 
(21.4%) patients. One undesirable effect was noticed in 19 
(67.9%) patients, simultaneously two — in 3 (10.7%) pati-
ents. Three and more undesirable effects were not registered. 
Absence of the toxic reactions of grade III and grade IV was 
detected. Intensity of the general complications in all cases 
corresponded to grade I according to the СТСАЕ 4.0.
El Sayed (2014) et al. and Hacker-Prietz (2015) reported 
cases of grade III proctitis post- HDR-EBT [5, 6]. In our stu-
dy radiation proctitis of grade I and grade II developed with 
the same frequency, 5 (17.9%) cases. The cases of grade III 
proctitis were not registered.
There was only grade I radiation cystitis noticed in 3 
(10.7%) patients. Grade I radiation epidermis was noticed in 1 
(3.6%) patients in our study. El Sayed (2014) et al. reported no 
patients developed grade III cystitis, but grade III dermatitis 
in that study was seen in 12% of patients [5].
Anaemia developed in 1 (3.6%) patient, leucopenia – in 
6 (21.4%) patients. Granulocytopenia, lymphopenia and 
thrombocytopenia were not detected. General type reaction 
(weakness, ailment, inappetency, low-grade fever) was noticed 
in 3 (10.7%) patients. Vomiting was not observed, sicchasia 
was registered in 1 (3.6%) patient, in this case this toxicity 
didn’t exceed grade I. 
Complete pathological response was noticed in 17 (60.7%) 
patients, pathological partial response was registered in 10 
(35.7%), absence of pathologic changes was noticed in 1 (3.6%) 
case. Our results are hopeful because not numerous research 
of HDR-EBT effectiveness for RC treatment showed complete 
pathological response up to 33% [6] and 47% [5].
Local recurrence developed within 2 first years of mo-
nitoring in 1 (3.6%) patient. No case of a distant metastasis 
during the whole period of monitoring was detected. 2 (7.1%) 
fatal cases were registered. The cause of death of both died 
persons was a pathology unrelated to cancer (in one case was 
an injury, in the second one – a heart failure).
Conclusions
The use of HDR-EBT as a start component of the neoadju-
vant locally advanced rectal cancer treatment is an acceptable 
modality with high pathological response rate as well as an 
acceptable toxicity profile.
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